Recognizing that eye diseases are multifactorial, the company's research team is developing bisistronic vectors. This approach packages two different transgenes into a single AAV vector, allowing a single gene therapy product to address multiple disease pathways simultaneously, a significant advancement over single-target therapies.
Complement Therapeutics intentionally built a presence across the UK, Germany, and the US to optimize talent acquisition. This cross-geographical structure allows them to hire the best experts in a specialized field like gene therapy, irrespective of their location, without being constrained by a single talent pool or dealing with complex relocations.
To ensure patients have active disease progression and increase the likelihood of demonstrating a treatment effect, the company mandates a six-month monitoring period before intervention. This filters out slow-progressing patients where a positive outcome would be difficult to prove, thereby de-risking the clinical trial.
Instead of waiting years for traditional vision preservation data, Complement Therapeutics' trial prospectively uses novel endpoints like ellipsoid zone attenuation and focal microperimetry. These measures are designed to show a signal of efficacy earlier and correlate better with functional outcomes, addressing a key challenge in slowly progressing diseases.
Despite having a cash runway through the end of its pivotal study, Complement's CEO emphasizes that a leader is 'never not raising money.' This approach allows the company to operate from a position of strength, focusing on execution while opportunistically checking the market temperature and planning for the next phase without financial pressure.